Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study

Affiliations

¹ Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy.
² Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy. luigi.bartalena@uninsubria.it.

Comment

M L Tanda et al. J Endocrinol Invest. 2020 Oct.

. 2020 Oct;43(10):1523-1525.

doi: 10.1007/s40618-020-01223-7. Epub 2020 Apr 18.

¹ Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy.
² Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy. luigi.bartalena@uninsubria.it.

No abstract available

Keywords: Exophthalmos; Graves’ disease; Graves’ orbitopathy; IGF-1 receptor; Teprotumumab; Thyroid eye disease.

Comment on

Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.